Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gsk (GLAXF) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$225.3 million.

  • Gsk's Interest Expenses fell 1115.01% to -$225.3 million in Q3 2025 from the same period last year, while for Dec 2025 it was -$674.8 million, marking a year-over-year increase of 5475.9%. This contributed to the annual value of $855.2 million for FY2024, which is 1319.06% down from last year.
  • As of Q3 2025, Gsk's Interest Expenses stood at -$225.3 million, which was down 1115.01% from -$245.5 million recorded in Q2 2025.
  • In the past 5 years, Gsk's Interest Expenses registered a high of -$202.7 million during Q3 2024, and its lowest value of -$1.0 billion during Q4 2022.
  • Its 5-year average for Interest Expenses is -$353.5 million, with a median of -$246.7 million in 2023.
  • In the last 5 years, Gsk's Interest Expenses soared by 1969.71% in 2021 and then tumbled by 30682.64% in 2022.
  • Gsk's Interest Expenses (Quarter) stood at -$253.4 million in 2021, then crashed by 306.83% to -$1.0 billion in 2022, then rose by 4.66% to -$983.0 million in 2023, then grew by 12.65% to -$858.7 million in 2024, then soared by 73.76% to -$225.3 million in 2025.
  • Its last three reported values are -$225.3 million in Q3 2025, -$245.5 million for Q2 2025, and -$204.0 million during Q1 2025.